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Abstract \  \
The aim o f this thesis was to investigate the link between changes in vascular reactivity 
and blood pressure in genetic and induced animal'models o f insulin resistance. Initially, the 
suitability of a pithed preparation to study vascular reactivity was established.
Attempts were made to alter the insulin sensitivity and hence the vascular reactivity o f a 
group of AP Wistar rats by placing the animals on a high fat diet. The diet failed to alter 
the vascular reactivity of the animals tested. Further studies in different rat strains using 
different diets would be needed to properly investigate the effects o f an induced insulin 
resistant state.
It was found that the insulin resistant obese AP Zucker rat had an increased vascular 
reactivity compared to the lean, insulin sensitive, AP Zucker rat. It was also found that the 
obese rat was hypertensive compared to the lean rat, although the difference in blood 
pressure was slight.
Pioglitazone, an insulin sensitising agent, decreased both blood pressure and vascular 
reactivity in the obese Zucker rat. However, despite having mild hypotensive effects, 
pioglitazone had no effect on the vascular reactivity of either the lean AP Zucker rat, the 
AP Wistar rat or the AP Spontaneously Hypertensive rat.
Two other insulin sensitising agents, vanadyl sulphate and ZD2079 (a 8 3 -adrenoceptor 
agonist) failed to alter the vascular reactivity of either lean or obese AP Zucker rats. This 
confounded the results obtained when using the other insulin sensitising agent 
pioglitazone.
Overall, these results indicate a strong association between insulin resistance, vascular 
reactivity and increased blood pressure but a direct cause and effect relationship has been 
difficult to demonstrate.
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Section One
Introduction
r i . n  Aims of this Project.
As will be discussed in detail later, it has been postulated in the literature that insulin 
resistance and associated hyperinsulinaemia have an association with a hypertensive state. 
Described below are the mechanisms by which insulin (and hence resistance to the action 
o f insulin) may both increase and decrease blood pressure (BP).
The aim of this project/thesis was to attempt to identify possible alterations in the 
peripheral vasculature of insulin resistant animal models and to assess the physiological 
significance of any such alterations. In particular it was hoped to determine whether 
functional differences between the vasculatures of insulin resistant and non insulin resistant 
animals could be demonstrated and whether these differences were related to blood 
pressure levels and sensitive to insulin sensitising agents.
fl.2) The Definition of Insulin Resistance
Insulin resistance (IR) is defined as a condition in which a sub-optimal metabolic 
response is produced by a given amount of insulin. The main impairment o f metabolism 
measured as a marker of IR is a decrease in insulin stimulated glucose uptake by skeletal 
muscle tissue. The main clinical markers of IR are impaired glucose tolerance and 
compensatory hyperinsulinaemia.
(1.3) Insulin Resistance in Disease States
Himscliffe (1936) first observed that diabetes mellitus occured in two forms. Himscliffe 
observed that some diabetic patients could be maintained by insulin injection and he 
termed this form of diabetes as type I (since termed insulin dependent diabetes mellitus or 
IDDM). The author also found that other patients had a form of diabetes which could not 
be controlled by exogenous insulin and he described this form of the disease as type II 
(since termed non insulin dependent diabetes mellitus or NIDDM).
IR occurs as a feature of both IDDM and NIDDM diabetes (DeFronzo et al., 1982) but is 
pathologically most important in NIDDM. Increased hepatic glucose production and 
impaired insulin secretion exist alongside peripheral IR in NIDDM but it is the IR which is 
described as the most important contributor to the overall hyperglycaemic state (Suter et 
al., 1992).
IR also occurs in other disease states such as dyslipidaemia (Hunt et al., 1989), other 
metabolic conditions such as leprechaunism, and hypertension (Ferranninl et al., 1987). 
The prevalence of IR and associated hyperinsulinaemia in hypertension will be discussed in 
more detail later.
(1.4) Insulin Resistance as a feature of "Svndrome X"
Reaven (1988) was the first to link a group of co-existing pathological conditions and 
describe their association as "Syndrome X". This syndrome describes a condition in which 
IR, hyperinsulinaemia, impaired glucose tolerance, dyslipidaemia and hypertension are all 
present. This condition is distinct from cardiological "Syndrome X", described by Kemp 
(1973), which describes a condition in which patients with anginal pain demonstrate 
electrocardiogram abnormalities on exercise but no angiographic indicators of 
atherosclerotic coronary artery disease. All following references to Syndrome X refer to the 
condition as described by Reaven rather than the cardiological condition described by 
Kemp.
Following Reaven, Kaplan (1989) described insulin resistance as the central feature of a 
group of linked conditions which predispose to cardiovascular disease. He described 
glucose intolerance, dyslipidaemia, hypertension and obesity as the "deadly quartet".
Table 1 The features of "Syndrome X" (from Reaven 1988)
Resistance to insulin-stimulated glucose uptake 
Glucose intolerance 
Hyperinsulinaemia 
Increased VLDL triglyceride level 
Decreased HDL cholesterol level 
Hypertension
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Possibly the most significant suggestion made by Reaven about Syndrome X is that 
insulin resistance may not be just a co-existing factor in the syndrome but may exist as a 
direct causal factor in the development of hypertension and coronary artery disease 
(especially due to the increased plasma insulin concentration which arises from the insulin 
resistant state). Experimental evidence for this was put forward.
Reaven described an experiment in which a group of rats were made insulin insensitive by 
replacing their normal diet with a high fructose diet (i.e., one in which all the carbohydrate 
was replaced with fructose). These rats went on to develop a degree of hypertension 
(compared to a group o f animals allowed a normal diet) associated with the development of 
insulin resistance and hyperinsulinaemia. Reaven concluded that in this experiment the 
high fructose diet caused a degree of insulin resistance which in turn lead to a 
compensatory hyperinsulinaemia. Reaven assumed that this hyperinsulinaemia had a direct 
causal relationship with the hypertensive change observed.
(1.5) Mechanisms bv which Insulin Resistance mav lead to Hypertension.
Various mechanisms have been put forward by several authors to explain how IR and 
associated hyperinsulinaemia may act to produce a hypertensive change. Brief outlines of 
each o f the various possible mechanisms are given below.
(1.5.1) Insulin and central nervous system (CNS) stimulation.
The literature has long suggested that an increased plasma insulin level (as found in 
insulin resistant states) can be associated with increased plasma catecholamine levels 
(Rowe et al., 1981 and Christensen et a!., 1980). An increased plasma catecholamine 
level is indicative of an increased level of sympathetic nervous system (SNS) activity. It 
has been demonstrated that insulin is capable of increasing the activity of the SNS. 
Stimulation of sympathetic nerves to the cardiovascular system can cause increases in 
vascular tone and increases in cardiac output (via increases in stroke volume and heart 
rate). The consequence of this stimulation would be an acute increase in systemic BP.
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Exogenous insulin infusion has been shown to increase the levels of sympathetic nervous 
activity in both animal models (Tomiyama et al., 1992 and Liang et al., 1982) and in 
humans (Lembo et al., 1992 and Anderson et al., 1991). Insulin may act to increase the 
activity of the SNS in several ways including alterations in baroreflex function, modulation 
of neurotransmitter release from peripheral nerve endings or direct stimulation o f the 
higher CNS centres.
Insulin binding has been demonstrated in the following areas of the hypothalamus: the 
median eminence (Landau et al., 1983), the dorsomedial hypothalamus, the arcuate 
nucleus and the ventromedial hypothalamus (Wilcox et al., 1989). Muntzel et al., (1995) 
demonstrated that one area of the hypothalamus in particular was important in the 
mediating the effects of insulin. This area is the anteroventral third ventricle hypothalamic 
(AV3V) region. Stimulation o f this region resulted in an increase in sympathetic outflow to 
lumbar regions but not in renal or adrenal nerves. Muntzel and co-workers demonstrated 
that lesioning of the AV3V region prevented insulin-induced increases in sympathetic 
nervous output.
Given that insulin may be able to induce BP increases by the above mechanism, it may be 
concluded that a long lasting hyperinsulinaemic state (present as part of an insulin resistant 
state) may result in increased sympathetic tone and thus predispose to a hypertensive state. 
Despite this, however, evidence exists which suggests that acute administration of 
physiological insulin concentrations to normotensive subjects produces increases in 
sympathetic outflow without any increase in BP. In fact, acute insulin administration can 
cause slight falls in BP even when accompanied by increases in heart rate which is an 
indication o f increased sympathetic drive (Baron et al., 1993). This observation would 
suggest that it may be unlikely that an increased sympathetic outflow driven by 
hyperinsulinaemia, without any other pathological change, would explain the hypertension 
seen in insulin resistance.
(1.5.2) Insulin and the Kidney.
The work of Guyton in the 1950's demonstrated that no hypertensive state can be 
maintained if renal function is normal. This is due to the effect o f "pressure natriuresis". 
Hypertensive changes induce increased natriuresis from normally functioning kidneys (thus 
leading to reductions in plasma volume) which would cause lowering of systemic BP. 
According to this principal, for insulin resistance to be a causal factor in a prolonged 
hypertensive change some renal pathology would have to be present.
Several authors have suggested that insulin can influence events in the kidney. Literature 
reports have indicated that insulin has activity in the kidney of dogs (DeFronzo et ai.,
1976) and humans (DeFronzo et al., 1975). These reports state that insulin acts to increase 
sodium (and hence water) reabsorption in the proximal convaluted tubule.
Endre et al., (1994) demonstrated that patients with a family history of hypertension were 
insulin insensitive in terms of the promotion of glucose uptake compared to a group of 
patients without a family history of hypertension (i.e., insulin resistant as per the normal 
definition of the term). Despite this, both groups of patients demonstrated equal levels of 
insulin sensitivity in insulin-induced tubular sodium reabsorption in the kidney. This study 
implies that the hyperinsulinaemia associated with Reaven's Syndrome X may produce 
chronic sodium retention and hence hypertension as renal insulin sensitivity is retained 
despite the presence of an overall insulin resistant state.
(1.5.3) Insulin as a Growth Factor
It has been demonstrated in several studies that insulin acts as a growth factor on vascular 
tissues. A review of these reports has been carried out by Stout (1990). A long term 
consequence of chronic hyperinsulinaemia may be a thickening of resistance vasculature 
leading to an increase in peripheral resistance. This increase in resistance may promote a 
hypertensive change.
(1.5.4) Insulin action on vascular reactivity.
Insulin may play a role in the regulation of systemic BP via its ability to induce relaxation 
in vascular tissue. The importance of changes in the peripheral vasculature in insulin 
resistant conditions (both clinical and experimental) in the overall hypertensive state 
associated with the condition have still not been clearly demonstrated.
Some evidence is begining to emerge demonstrating the importance of peripheral 
mechanisms in the hypertensive condition of experimental IR models. Zemel et al., (1992) 
demonstrated that the insulin resistant obese Zucker rat was hypertensive compared to its 
lean counterparts without CNS contribution. Zemel demonstrated this by treating conscious 
obese rats with the ganglionic blocking agent Bcolid (chlorisondamine chloride) and 
demonstrating that they remained hypertensive compared to lean rats treated with the same 
agent.
In another study, Zemel et al., (1991) demonstrated that aortae from obese rats were 
hyper-reactive to vasoconstrictor agents in vitro compared with tissues taken from lean 
rats. The authors went on to demonstrate that tissues obtained from the lean animals were 
sensitive to insulin induced relaxation but tissues from the obese animals were insensitive. 
Cox and Kikta (1992) also demonstrated that aortae from obese Zucker rats demonstrated 
a greater response to contractile agents compared with tissues obtained from lean animals. 
When these results are considered alongside the in vivo data obtained using ganglionic 
blockade outlined above, Zemel's work indicates that obese Zucker rats possess differences 
in their peripheral vasculature compared to their lean counterparts which may predispose 
them to hypertension.
Other studies have been published which support the results o f Zemel and his co-workers. 
As far back as 1977, Alexander and C ake were able to demonstrate that insulin attenuated 
constrictor responses in the tail artery of insulin sensitive male rats (these results could not 
be repeated in female animals). In both non-obese dogs and in patients, acute and more 
chronic hyperinsulinaemia produced reductions in both total peripheral resistance 
(indicating a vascular relaxation in resistance vessels) and BP. These observations were
made despite increases in sympathetic nervous activity occurring simultaneously (Hall et 
al., 1992, Anderson et al., 1991 and W eidmann, 1991).
In a more direct ex vivo study McNally et al., (1995) obtained resistance vessels from 
healthy volunteers and assessed the sensitivity of these vessels to constrictor agents in the ' 
presence and absence of insulin. It was found that noradrenaline-induced contractions of 
the vessels were significantly attenuated by insulin. Increasing levels of insulin caused 
dose-related attenuation of noradrenaline without affecting acetylcholine induced relaxtion 
in this study. This study confirms that the attenuation of contractile events produced by 
insulin in tissues obtained from rats as seen by Zemel and co-workers may occur in humans 
too.
Conversely, it has been demonstrated that insulin fails to cause any decrease in the 
peripheral vascular resistance in obese dogs (Hall et al., 1992). Patients with essential 
hypertension and NIDDM have both been shown to have an increased responsiveness to 
vasoconstrictor agents (F errari and W eidm ann, 1991).
From the studies outlined above, it may be deduced that insulin has a potential 
physiological relaxant role in the peripheral vasculature. It may be expected then, in normal 
animals and man, that the hyperinsulinaemia present as part of an insulin resistant state 
should produce a hypotension rather than the hypertension which is actually seen.
Evidence from in vitro testing of tissues from insulin resistant models and in vivo 
examinations of insulin resistant models and patients suggests, however, that they are 
insensitive to this relaxant effect of insulin. If  insulin does indeed play a role in the normal 
control of vascular tone, resistance to this relaxant modulation may contribute to a 
hypertensive change.
The mechanisms by which pathological hyperinsulinaemia or insulin resistance may 
modulate blood pressure, as discussed in this section, are summarised in table two (on page 
19a).
(1.6) Clinical observations and Population Studies 
1.6 . 1  Clinical studies of hvnertensive patients
I
The first study of the role of insulin and BP regulation was published in 1966 in which 
W elborn et al., demonstrated that a group o f 19 hypertensive subjects (who had diastolic 
BP above 110 mmHg) had elevated plasma insulin levels compared to a group o f 45 
normotensive subjects. It was found that the relationship between plasma insulin and 
diastolic BP was present in the hypertensive group even when the factors o f age and anti­
hypertensive therapy were taken into account. Interest in the potential link between plasma 
insulin levels (as well as IR and its associated features) and BP levels grew in the mid 
1980's following Reaven's suggestion that IR, and hence hyperinsulinaemia, may play a 
causal role in the development of hypertension.
F errannin l et al., in 1987, published a study carried out in a small group of subjects, 7 
males and 6  females, with moderate to severe untreated hypertension. These hypertensive 
subjects were aged 38 + 2 years and had a body mass index (BMI) of 26 + 1 (i.e., 
moderately overweight). The subjects BP levels were 165 + 5 mmHg (systolic), 132 + 4 
mmHg (mean) and 112 + 3 mmHg (diastolic). When compared to a normotensive control 
group (of 7 males and 4 females), the hypertensive subjects demonstrated a significantly 
lower insulin-stimulated glucose uptake. During an insulin infusion to maintain a steady 
plasma insulin concentration (60 pU ml"l), insulin mediated glucose disposal (IMGD) was 
3.80 + 0.32 mg kg’  ^mim^ in the hypertensive group and 6.31 + 0.42 mg kg'^ m in 'l in the 
control group ( f  <0.001). It was also found that glucose uptake was inversley related to 
systolic BP and mean BP (r=0.76 for both, P<0.001).
In a slightly larger study, Pollare et al., (1990) studied the plasma insulin, plasma glucose 
and rate of IMGD in a group of 143 newly diagnosed hypertensive subjects and a control 
group of 51 normotensive subjects. The hypertensive subjects were divided into non-obese 
and obese groups using a body mass index (BMI) of 27 for male subjects and 26 for 
females as cut-off points. The authors found that IMGD was significantly decreased in both 
the obese hypertensives (5.1 + 2.1 mg kg“l min"^, P<0.05) and the non-obese hypertensives
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(7.2 + 2.1 mg kg"l m in'l, P<0.05) when compared to the normotensive group (8.4 +1.8  mg 
kg 'l m in'l). The authors also found that after controlling for sex, age and BMI the 
hypertensive subjects had a higher fasting plasma insulin than the normotensive subjects 
(P<0.05).
The three studies outlined above demonstrated that relatively small groups o f 
hypertensive patients (both obese and non-obese) had some o f the features o f IR. Lind, 
Berne and Lithell, (1995) published a study in which the prevalence o f IR in a large group 
o f hypertensive subjects was evaluated. The hypertensive subject group was composed of 
420 patients with diastolic BP of over 95 mmHg either never treated with anti-hypertensive 
therapy or placed on placebo for 4 weeks prior to the study. The hypertensive group were 
also selected on the basis of a fasting blood glucose level of > 6.7 mmol k h  A "healthy" 
control group was also tested. This control group consisted o f 51 subjects with a diastolic 
BP below 95 mmHg and fasting blood glucose of < 6.7 mmol k h  Using a value for IMGD 
of 4.4 mg kg 'l m in'l as a cut-off (as accepted in most of the literature), it was found that 27 
% of the hypertensive group were insulin resistant. The authors found that the mean IMGD 
value in the control group tested was 8.2 + 1.9 mg kg-1 min"k The authors also suggested 
that the results from eight different studies in their laboratory on subjects with normal 
insulin sensitivity indicated that a IMGD value of 5.5 mg kg'^ min'^ was a more accurate 
cut-off level to use to define clinical insulin resistance. When applying this 5.5 mg kg"! 
m in'l value, 43 % of the hypertensive subjects tested in this study were found to be insulin 
resistant.
The figure of 43 % quoted by Lind et al., above is similar to that quoted by Zavaroni et 
al., (1991) in a study of the incidence of hyperinsulinaemia in another group o f patients 
with essential hypertension. This study involved 41 hypertensive subjects and a 
normotensive group of 41 age matched subjects. It was found that 90 % of the 
normotensive subjects had a plasma insulin level of <80 pU mk^ 2 hours following an oral 
glucose load. Using the figure of 80 pU mk^ as a cut-off it was found that 41 % of the 
hypertensive subjects were hyperinsulinaemic.
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1.6.2 Epidemiological studies o f insulinaemic/insulin resistant patients
The studies described above in section 1.5.1 indicate that IR and associated 
hyperinsulinaemia are features of at least a percentage (although by no means all) o f 
subjects with essential hypertension. Despite this evidence a link between insulin 
sensitivity and associated hyperinsulinaemia with BP levels has been difficult to 
demonstrate in population studies. In the early studies of this relationship investigators 
examined the assumption that insulinaemia alone was the causal factor in BP elevation 
(due to increased CNS output and decreased renal output as described in section 1.4 
above). Due to this assumption most of the early studies of IR and BP concentrated purely 
on the potential link between plasma insulin levels and BP levels.
One of the most widely quoted papers in which a positive correlation between plasma 
insulin levels and BP was demonstrated was that published by M odan et al., (1985). This 
study was part of a larger study entitled the "Israel study of Glucose intolerance. Obesity 
and Hypertension". A representative sample of 2,769 subjects was selected from the 
original sample of 5,711 subjects. After accounting for the removal of refusals, known 
diabetics and technical problems 2,475 subjects underwent a full oral glucose tolerance 
test. Within this sample it was found that hypertension and glucose intolerance showed a 
highly significant association (P<0 .0 0 0 1 ) which was independent of sex, age, obesity and 
anti-hypertensive medication. Although significant, the relationship between insulin level 
and hypertension was less strong than that of obesity to hypertension which, in turn, was 
less strong than that o f glucose intolerance to hypertension. The strongest correlation with 
hypertension was a condition in which hyperinsulinaemia, obesity and glucose intolerance 
were all present.
The type o f results obtained by Modan et. al., have also been demonstrated by Lucas et 
al., (1985) in a group of 33 "very obese" women. Lucas and co-workers found that both 
systolic and diastolic BP were significantly related to fasting plasma insulin levels even 
when age, weight and serum glucose levels were taken into account. It must be noted that 
in this study the relationship between insulin and BP was strongest in subjects with a 
family history of hypertension. In another study of obese subjects (10 women and 25 men),
11
Manicardi et al., (1986) found a significant correlation between 2 hour post load insulin 
levels and BP in hypertensive but not normotensive subjects. Rose et al., (1986) made a 
study of 19 Vietnam veterans with leg amputation just below the knee and a comparison 
group of Veterans with an arm amputation. The important difference between the two 
groups was the fact that the subjects with an arm amputation were more mobile than the 
subjects with a leg amputation who could exercise less. It was found that the subjects with 
a leg amputation had a greater BMI than the comparator group. The authors found that both 
insulin level following an oral glucose load and body fat content were strongly and 
independently correlated to diastolic BP.
The studies outlined above were mostly composed of obese white subjects. It is obvious 
from the literature that the relationship between insulin and BP is much less consistent 
across other ethnic groups. In a study of Pima Indians (native Americans from the Gila 
river Indian community in Phoenix, Arizona) carried out by Saad et al., (1990), it was 
found that 2033 subjects, who were taking no anti-hypertensive or diabetic therapy, 
demonstrated no correlation between their fasting plasma insulin levels and their BP. In a 
larger population, which was not selected on the basis of therapy taken, it was found that 
hypertension was positively correlated with age, male sex, BMI, glucose tolerance and 
fasting insulin levels (but not 2 hour post load insulin levels). The authors suggest that the 
antihypertensive therapies taken by some subjects were affecting plasma insulin levels and 
may have altered the insulin and BP relationship in this larger population.
In 1991 Saad et al., again demonstrated that no correlation existed between plasma 
insulin levels and BP in a group of 116 Pima Indians. In this new study a group o f white 
(n=53) and a group of black (n=42) North Americans were also tested. It was found that 
after accounting for age, sex and BMI, mean BP was significantly correlated to fasting 
insulin levels (P<0.01) in the white population alone.
Cruickshank et al., (1991) also described an ethnically mixed study consisting o f 106 
Afro-Caribbean, 107 Gujerati Indian and 101 white European subjects. In this study no 
correlation between any insulin measure and BP could be found in any of the groups. 
Cambien et al., (1987) and Muller et al., (1993) described different studies o f white
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subjects in which a strong correlation between hypertension and an elevation of BMI, 
plasma glucose and plasma insulin was found but no correlation between insulin levels and 
BP was found when the other factors were taken into account.
1.6.3 Blood pressure levels in two other hvnerinsulinaemic conditions
Most of the earlier literature studies of IR outlined above assume that the compensatory 
hyperinsulinaemia resulting from the insulin resistant state to be the potential driving force 
behind a hypertensive change via increased CNS output, decreased renal function or both 
(these mechanisms were described in sections 1.4.1 and 1.4.2 above). Several studies 
involving BP measurement have been carried out in patients with conditions other than IR 
in which a hyperinsulinaemic state is present.
Vettor et al., (1994) describe a study in 37 patients with insulinoma (insulin secreting 
tumours) admitted to the Institute Semeiotica Medica in Padua Italy between 1966 and 
1990. These patients were 21 females and 16 males of average age 47.1 +2.8  years with a 
mean average o f symptoms of 33.1 + 5.1 months. A control group of patients, without 
insulinoma, of equivalent age and BMI to the insulinoma bearing patients were also 
examined. It was found that the insulinoma patients had much higher plasma insulin levels 
than the control subjects (407.2 + 96 pmol 1"! against 42.0 + 4.2 pmol k^) but had no 
significant differences in either systolic BP (135 + 3 mmHg against 132 + 8  mmHg) or 
diastolic BP (87 + 1 mmHg against 8 6 + 1  mmHg). However it must be noted that the BP 
of the patients fell slightly following removal of the insulinoma. This BP fall was small but 
statistically significant (the diastolic BP fell from 8 7 + 1  mmHg with the tumour present to 
80 + 2 mmHg after its removal, P<0.05).
Tsutsu et al., (1990) also studied the BP levels of a small number of patients with 
insulinomas. The authors found that 7 patients with a mean plasma insulin level o f 568 
pmol k^ prior to the removal of their tumour had a mean systolic BP of 127+15 mmHg 
and a mean diastolic pressure of 74 + 10 mmHg (i.e., below the level of clinical 
hypertension). After the removal o f the tumour the patients systolic pressure fell slightly to 
120 + 14 mmHg but no correlation existed between BP fall and the fall in plasma insulin
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levels. Pontiroli et al., (1992) described a study of 13 patients with insulinoma and 6 with 
"non-tumour hypoglycaemia and hyperinsulinaemia". It was found that 3 out o f the 19 
patients were hypertensive and that this figure fell to one patient when those patients with a 
history of familial hypertension were excluded. Sawicki et al., (1991) published a 
comparative study o f 34 patients with insulinoma and 34 age and sex matched controls. It 
was found that both groups had very similar BP levels (131/81 mmHg in the insulinomia 
patients and 130/80 mmHg in the control group).
A much larger retrospective study of the BP levels o f patients with insulinomas was 
described by O ’Brien et al., (1991). The BP levels of 250 patients admitted to the Mayo 
Clinic between 1927-1991 were measured. Nine patients were excluded on the grounds that 
they were being treated for pre-existing hypertension. In the remaining group o f 241 
patients, who had a median age of 41 years and a median duration of symptoms o f 1.9 
years, it was found that 31 patients (12 %) had clinical hypertension (i.e., a BP level greater 
than 145/90 mmHg). This figure did not exceed that expected from a representative sample 
of the general population.
Polycystic ovary syndrome (PCO) is a disorder of women characterised by chronic 
anovulation and hyperandrogenism. The condition is associated with insulin resistance, 
hyperinsulinaemia and an increase in android obesity. Chang et al., (1983) demonstrated 
that IR and hyperinsulinaemia were present in lean patients with PCO indicating that PCO 
is an insulin resistant state independent of obesity. In 1992 Zim m erm an et al., published a 
study of 14 subjects with PCO (10 obese and 4 non-obese) alongside a control group of 
insulin sensitive subjects without PCO. It was found that the two groups had very similar 
BP levels, the PCO group having mean blood pressure values of 121/76 mmHg and the 
control group having mean blood pressure values of 118/73mmHg.
1.6.4 Insulin Resistance not hyperinsulinaemia related to Blood Pressure
Saad et al., (1994) demonstrated, in a group of 183 non-diabetic subjects, that 
hypertensive and normotensive subjects did not have significantly different fasting plasma 
insulin levels. Despite this the authors found a significantly higher 2 hour insulin level
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following an oral glucose load in the hypertensive subjects compared to the normotensive 
subjects. From this observation the authors concluded that IR itself had a greater 
association with BP than compensatory hyperinsulinaemia. This observation fits with the 
data obtained from studies in groups o f hypertensive subjects by both Ferraninni et al., 
and Pollare et al., (as described above in section 1.6.1 above). These studies linked direct 
measurements of insulin sensitivity (such as insulin mediated glucose disposal) with BP 
levels and demonstrated a positive correlation between the two.
Despite the fact that measurements of insulin sensitivity appear to be more closely related 
to BP levels, and to hypertension in particular, it must be added that the ethnic differences 
seen in studies of pure hyperinsulinaemia are still present in the studies involving insulin 
sensitivity. Studies have demonstrated that Pima Indians are insulin resistant as well as 
hyperinsulinaemic but not hypertensive (Saad et al., 1991). As described previously, 
another condition in which IR is present is polycystic ovary syndrome. Zimmerman et al.,
(1992) failed to find evidence of BP changes in 14 patients with polycystic ovary syndrome 
despite profound IR.
Summary
The literature evidence described above (in all o f section 1.6) points to the fact that at 
least a proportion of essential hypertensives demonstrate some of the features of IR, 
especially hyperinsulinaemia. It is also clear that a condition in which insulin resistance, 
hyperinsulinaemia and android obesity are all present (i.e., the various components of 
Syndrome X) is strongly correlated with an increased BP level. The link between pure 
hyperinsuilinaemia and BP is at best controversial (i.e., when other factors, especially 
obesity, are corrected for). Insulinaemic conditions, such as polycystic ovary syndrome and 
insulin secreting tumours, in themselves are not linked with increases in BP. More recently 
a view is emerging that insulin sensitivity (and hence insulin resistance) rather than 
hyperinsulinaemia has a stronger link with BP levels but again, due to factors such as 
ethnic differences, the evidence for this is not conclusive when other factors are corrected 
for.
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A potential weakness in the literature on insulin resistance and its link with BP levels, 
especially in the population studies described above, is that many authors have 
concentrated on attempting to demonstrate a link between a single facet o f Syndrome X 
(especially hyperinsulinaemia) with hypertension. In ^oing this the authors have selected 
groups of subjects who do not demonstrate all the features o f Syndrome X (obesity tends to 
be corrected for especially). As insulin resistance may be the causal factor behind these 
other conditions, the authors risk selecting a non-typical population of insulin resitant 
subjects to study.
(1.7) Animal Models of Insulin Resistance.
Animal models of IR can be divided into two main categories: induced models (in which 
IR is induced mostly by dietary alteration) and spontaneous (i.e., genetic) models.
1.7.1 Dietary (Induced) Models.
Several studies have linked alterations in diet with decreases in insulin sensitivity and 
increases in vascular reactivity. Alterations in diet that have been shown to be effective in 
the induction of a hypertensive change include increases in the sugar content. One o f the 
earliest of these studies was that carried out by Reaven and co-workers which was outlined 
in section 1.3 above. Martinez et al., (1994) also demonstrated that a high fructose diet 
induced insulin resistance, hyperinsulinaemia and a rise in BP in normal mongrel dogs 
rather than in rats. Zein et al., (1990) demonstrated that a diet high in sucrose could further 
elevate the BP of the already hypertensive SH rat.
Other workers have demonstrated that IR may be induced by increases in dietary fat 
composition. Pedersen et al., (1991) produced IR and a decrease in the expression of glut- 
4 (a glucose transporter) by a imposing a high fat diet on a group of rats. Storlien et al.,
(1991) also induced an insulin resistant state in rats by means of a high saturated fat diet.
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1.7.2. Spontaneous Models.
The two main animal models of IR are the ob/ob mouse and the obese Zucker rat. The 
Zucker rat is a spontaneously obese animal and was first described by Zucker and Zucker 
in 1967. The obese Zucker rat has two distinct two phenotypes, lean and obese. The obese 
rat inherits its condition due to an autosomal recessive trait (Bray 1977). The obese rat has 
been described as a potential model of both obesity and of hypertension as the obese rat 
demonstrates a higher BP than its lean littermate (Boese et al., 1986 and Kasiske et al., 
1985). The obese Zucker rat has been described by Kurtz et al., (1989) as insulin resistant 
(and hypertensive) compared to lean littermates.
The ob/ob mouse is also a spontaneously obese animal model with a degree of insulin 
resistance. The ob/ob mouse possess genetically transmitted obesity, hyperglycaemia and 
hyperinsulinaemia (Flatt and Bailey, 1981).
The spontaneously hypertensive (SH) rat has also been described as another potential 
spontaneous model of IR. The SH rat has long been recognised as a model of hypertension 
and also of increased vascular reactivity (Field et al., 1972). Current literature reports are 
divided as to whether the SH rat may be described as an IR model eg., Hulman et al.,
(1993) found the SH rat to be insulin resistant while Buchanan et al., (1992) failed to 
demonstrate IR in the strain.
(1.8) Potential Drug Treatments of Insulin Resistance.
Literature reports have described a number of chemical agents which increase insulin 
sensitivity and are therefore of use in reversing insulin resistance in animal models. 
Agonists of a recently described 8 -adrenoceptor agonist subtype (the 8 3 -adrenoceptor) 
have been shown to be effective in increasing insulin sensitivity in animal models. 
Cawthorne et al., (1992) described the effects of the selective 8 3 -adrenoceptor agonist 
BRL 35135 in the obese Zucker rat. In this study it was found that BRL 35135 normalised 
the glycaemic state of the obese rat at a dose of 23.4 pg kg"  ^ dayL  The authors also
17
demonstrated that BRL 35135 was effective clinically in improving glucose tolerance when 
dosed to obese subjects. Connacher et al., (1992) also demonstrated that another B3 - 
adrenoceptor agonist, BRL 26830A, was effective in reducing plasma insulin in obese 
subjects. Wilbraham et ai., (1994) demonstrated that ZD2079 was capable of improving 
glucose tolerance and decreasing plasma glucose and insulin when dosed to insulin 
resistant, ob/ob mice.
Vanadium containing compounds have been described in the literature as being o f use in 
IR animal models. Lonnroth et al., (1993) suggested that vanadate acts in an insulin-like 
manner in human adipocytes (i.e., that vanadate acts as an insulin mimetic in these cells). 
This observation was supported by Wallburg-Henriksson et al., (1993) who demonstrated 
that vanadate was capable o f increasing glucose oxidation and synthesis in the skeletal 
muscle o f obese subjects. Brichard et al., (1990) described improvements in glucose 
homeostasis in the insulin resistant ob/ob mouse as a consequence of sodium orthovanadate 
administration. More directly relevant in the context of the peripheral vascular defects of 
insulin resistant animal models are the observations of Ozcelikay et al., (1994). These 
authors described a normalisation of the increased vascular responsiveness of aortae from 
streptozocin (STZ) treated diabetic rats following vanadyl sulphate dosing.
One of the most interesting and most studied class of compounds which may be o f use in 
insulin resistant states is the thiazolidenediones. This class of agent includes pioglitazone, 
ciglitazone and CS-045. These agents have been shown to be true insulin sensitising agents 
in that they require the presence of insulin to exert a physiological effect (Hofmann and 
Colca 1992).
CS-045 has been shown to improve insulin sensitivity and lipid disorders. Fujiwara et 
al., (1991) demonstrated that chronic CS-045 treatment in diabetic mice (db/db strain) 
produced reductions in hyperglycaemia, glucose intolerance, plasma triglycerides and free 
fatty acid levels. Despite these results, CS-045 has been shown to be ineffective in another 
diabetic model, the STZ treated mouse (Fujiwara et al., 1988). The agent has also been 
shown to be effective in patients as well as in animal models. Iwamoto et al., (1991) 
demonstrated that CS-045 treatment of patients with NIDDM produced an improvement in 
glucose tolerance without a stimulation of insulin secretion (which suggests that an
18
increase in insulin sensitivity had occured). These results were supported by Suter et al.,
(1992) who also demonstrated improvements in glucose tolerance, plasma insulin levels 
and plasma free-fatty acid levels in CS-045 treated NIDDM patients.
Pioglitazone, another thiazolidenedione agent, has also been shown to be useful in 
reducing the level o f IR in animal models (Ikeda et al., 1990 and Sugiyama et al., 1990). 
Pioglitazone has also been shown to have effects on BP in animal models o f IR. Kemnitz 
et al., (1994) demonstrated that pioglitazone treatment of obese insulin resistant Rhesus 
monkeys produced reductions in plasma insulin and glucose and a significant fall in mean 
arterial BP.
n  .9) Aims o f this Project - Restatement.
As outlined in the introduction above, it has been postulated in the literature that IR and 
associated hyperinsulinaemia have an association with a hypertensive state. Also described 
above are the mechanisms by which insulin (and hence resistance to the action o f insulin) 
may both increase and decrease BP.
The aim o f this project/thesis was to attempt to identify possible alterations in the 
peripheral vasculature of insulin resistant animal models and to assess the physiological 
significance o f any such alterations. In particular it was hoped to determine whether 
functional differences between the vasculatures of insulin resistant and non insulin resistant 
animals could be demonstrated and whether these differences were related to BP levels and 
sensitive to insulin sensitising agents.
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Section Two 
Materials and Methods
(2A) Materials
"Intraval" anaesthetic (thiopentone sodium 2.5%, May & Baker)
"Saffan" anaesthetic (steroid mixture consisting of alphaxalone and alphadolene acetate 
with 20% w/v poiyoxyethylated castor oil, Pitman-Moore)
"Fluothane" inhalation anaesthetic (Halothane, Zeneca Pharmaceuticals)
Heparin sodium ("Multiparin", CP Pharmaceuticals) - 5000 units m pl
Phenylephrine (L-phenylephrine hydrochloride. Sigma)
Angiotensin II (Sigma)
Pioglitazone (Zeneca Pharmaceuticals)
ZD2079 (Zeneca Pharmaceuticals)
Vanadyl sulphate (vanadyl sulphate trihydrate, Aldrich)
(2.2) Animals Tested
Alderley Park Wistar strain rat (AP Wistar rat)
Alderley Park Spontaneously Hypertensive strain rat (AP SH rat)
Alderley Park (AP) lean Zucker rat 
Alderley Park (AP) obese Zucker rat
21
(23)  Methods
j2 3 A) Measurement o f Blood Pressure and Vascular Reactivity in Conscious and 
Anaesthetised Rats
Male lean and obese Zucker rats were anaesthetised with Saffan (10 mg kg-l) via the tail 
vein. A small incision was made in the throat of the animal and the right jugular vein and 
right carotid artery were exposed. The two blood vessels were cannulated with sealed 
cannulae containing heparinised saline. The arterial cannula consisted of a piece o f 
polythene tubing with an external diameter o f 1.27 mm and an internal diameter o f 0.86 
mm (Portex code 800/100/260/100). The venous cannula was a piece o f polythene tubing 
with an external diameter of 0.8 mm and an internal diameter of 0.4 mm (Portex code 
800/100/140/100).The two cannulae were sealed with a pin to prevent both blood loss from 
the animal and blood leakage into the cannula which may have caused clotting and hence 
blockage.
A trochar was used to punch a hole in the nape of the animals neck and left in place. The 
two cannulae were then exteriorised using the trochar. The incision in the throat o f the 
animal was closed using veterinary autoclips.
On the day following surgery, the rats were placed in restraining tubes. The carotid 
cannula was clamped with a pair o f Spencer-Wells artery clamps to prevent blood loss 
from the rat and the pin removed. The now open end of the cannula was then connected to 
a heparinised saline filled pressure transducer to enable blood pressure and heart rate 
recordings to be made. The blood pressure and heart rate recordings were made via a 
Lectromed MT8 P amplifier unit and Astro Med MT95000 16 channel chart recorder.
The animals were allowed to settle in the restraining tubes until steady blood pressure and 
heart rate values were obtained (typically 2 0  to 25 minutes). Following this, increasing 
doses of pressor agent (either phenylephrine or angiotensin II) were administered via the 
jugular vein cannula. The maximal rise in diastolic pressure above baseline following the 
administration of the pressor agent was measured.
2 2
The typical BP response to phenylepherine was biphasic in nature. A very rapid rise in BP 
was followed by a longer lasting plateau phase. The diastolic pressure measurement taken 
was at the secondary, more sustained, phase o f the response as this part o f the response 
'would be less likely to be affected by speed o f administration. The BP of the animal was 
allowed to return to the original baseline before the next pressor response was induced.
(2.3.2) Measurement of Vascular Reactivity in Pithed Rat<^
Obese and lean Zucker rats o f either sex were anaesthetised with Saffan (10 mg k g - v i a  
the tail vein. The trachea of the rat was exposed and cannulated to enable artificial 
respiration. The rat was then pithed with a metal pithing rod via the eye-orbit and then 
immediately attached to a small rodent ventilator (Searle Instruments, model 5119). The 
ventilator supplied a 40 % oxygen and 60 % nitrogen mixture at a volume of 4 ml and at a 
rate of 55 strokes min’k
The right carotid artery of the animal was cannulated to enable BP recordings to be made. 
The arterial cannula consisted of a piece of polythene tubing with an external diameter of 
1.27 mm and an internal diameter of 0.86 mm (Portex code 800/100/260/100). The right 
jugular vein was cannulated to enable drug administration to occur. The venous cannula 
was a piece of polythene tubing with an external diameter o f 0 . 8  mm and an internal 
diameter o f 0.4 mm (Portex code 800/100/140/100). The body temperature o f the animal 
was maintained at 38°C with a heated blanket. The temperature o f the heated blanket was 
regulated via a thermostat connected to a rectal thermometer (Bioscience CFP 8185).
The carotid artery cannula (filled with heparinised saline) was connected in turn to a 
saline filled pressure transducer (Bell & Howell 4-422-001). This transducer was in turn 
connected to a combined amplifier and chart recorder (Lectromed Multitrace 2 ) which was 
used to record BP measurements. The BP signal was differentiated to obtain a heart rate 
measurement which was also recorded.
After surgery was completed, the animal was allowed to equilibrate until steady baseline 
BP and heart rate values were obtained (this typically took around 20 to 25 minutes).
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Following this, increasing doses o f pressor agent (either phenyleplirine or angiotensin II) 
were administered via the jugular vein cannula. The maximal rise in diastolic pressure 
above baseline following the administration of the pressor agent was measured.
I :
(2.3.3) Measurements of Blood Pressure and Heart Rate in Conscious Rats bv Radio- 
Telemetry
The Data Sciences radio-telemetry equipment provides a means of measuring the BP, 
heart rate and activity o f a conscious unrestrained rat remotely. The measurements obtained 
using this system are free from the stress induced by surgery and restraint.
The Data Sciences radio-telemetry system comprises of a pressure transducer (TA IIP  A- 
C40) implanted in the abdomen of a rat which transmits a radio signal indicating the 
pressure in the aorta of the animal. The implant contains a magnetic switch which can be 
used to turn the unit off and on (thus prolonging battery life). The signal is sent to a 
receiver (RA 1010) placed under the plastic cage of the animal and evaluated and recorded 
automatically by prewritten computer software (Data Quest IV installed on an AST 486 
PC).
The system measures absolute pressure within the animal. Atmospheric pressure is 
measured within the animal housing area (by a pressure reference unit. C l IPR) and is 
subtracted from the pressure recorded within the animal. This correction thus cancels out 
barometric changes over the course of an experiment and prevents drift in the calibration o f 
the implanted transducer.
The upper and lower pressure readings obtained by the system indicate the systolic and 
diastolic blood pressures of the animal and the number o f pressure peaks per unit time 
indicate the heart rate of the animal. Alterations in the signal strength detected at the 
receiver are used to give an indication of animal movement and are stored by the computer 
as an activity score.
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Implantation Methodology
Rats were anaesthetised with "Fluothane” inhalation anaesthetic. The abdomen o f the rat 
was then shaved and die skin of the shaved area was coated with a topical disinfectant. An 
incision was made with a scalpel on the outer skin to expose the abdominal muscle wall. 
The muscle wall was then cut along the mid-line and opened. The viscera o f the animal 
was held back with retractors and the abdominal aorta located. The aorta was cleared of 
connective tissue over a 2-3 cm length and carefully separated from the associated vena 
cava.
A tie was placed loosely under the aorta. The tie was then lifted to occlude the aorta. A 
puncture was made in the vessel with a 2 1  gauge needle (Micro Lance, Becton Dickson) 
the tip of which had been bent to approximately 90 degrees to the needle shaft. Using the 
bevel of the needle (held in place in the vessel), the tip of a Data Sciences rodent implant 
was carefully inserted into the puncture in the blood vessel. Once the tip o f the implant 
catheter had been pushed further into the aorta the needle was removed. A small drop of 
surgical glue (Vet Bond, 3M) was run down the exposed catheter length to form a seal on 
the interface between the catheter and the blood vessel. Care was taken to avoid the fixing 
of the cannula tip into the aorta around the area where the renal arteries branch from the 
larger vessel. This was done to avoid the possibility of either the cannula, or the glue used 
to fix it into place, causing a constriction of the renal vessels. Physiological saline was run 
across the base of the catheter to harden and fix the glue.
A small piece of sterile paper was then placed across the aorta on top of the inserted 
cannula and glued into place. This paper acted to fix the aorta around the area o f the 
catheter insert to prevent movement which may have lead to the catheter pulling on the 
aorta (threatening the integrity of the blood vessel).
The implant body was coated in a fine mesh which formed a lip on one side o f the 
implant. This lip was used to stitch the implant onto the inside wall of the abdominal cavity 
to prevent movement o f the implant within the abdomen (again to reduce the possibility of 
movement o f the implant body which may place strain on the blood vessel). The abdominal
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muscles were then closed with a single continuous stitch. The ends o f the abdominal 
stitching were trimmed and the skin of the animal closed with surgical autoclips.
Following surgery, the rat was placed in a plastic based cage containing sawdust. This 
type o f animal housing was used for two reasons. If placed in a normal metal cage the rat 
could cause removal of the autoclips holding the recovering abdominal skin by contact 
with the metal bars. A metal cage would also interfere with the signal from the implant. 
Seven days after surgery the autoclips were removed.
Once the autoclips were removed from the animal, the implanted transducer was turned 
on with a magnet. The animals activity pattern was observed over several days to ensure 
normal activity rhythms were occurring (i.e., that the animal was active during the night 
cycle and dormant during the day cycle). Typically the normal activity pattern returned 
within seven days. The presence of this normal activity pattern indicated that the animal 
was fully recovered from the stress of surgery and autoclip removal.
Study Protocol
The telemetry study carried out for this project used male AP SH rats aged approximately 
3 months at the time of surgery and implantation. Implantation was impossible on younger 
animals due to the size of the implant body. Once the autoclips were removed after surgery 
and the animals had fully recovered, the animals were orally dosed once daily with water to 
accustom them to the dosing procedure. This acclimatisation period lasted for 
approximately five days.
Once oral dosing failed to produce stress responses in the animals and steady 
haemodynamic measurements were observed the rats were dosed with polysorbate (i.e., 
drug vehicle). Polysorbate was dosed once daily for seven days. At the end o f this control 
period pioglitazone was dosed at 30 mg kg-1 to each animal once daily for a further period 
o f seven days.
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(2.3.4) High Fat Diet Preparation
The high fat diet was composed o f 60 % ground rat diet (Scientific Services), 10 % caesin 
(Sigma) and 30 % lard (Co-op). A control group of rats was fed ground rat diet only (i.e., 
the same ground diet as in the high fat diet but without the supplementary caesin and lard).
Each kilogram of the high fat diet was prepared in the following manner. 600 g o f ground 
diet was mixed with 100 g of caesin in a blender. Once these two powders were thoroughly 
mixed, 300 g o f lard was added to the mixture. The lard was added and blended into the 
mixture in four to five portions rather than a single block to enable efficient mixing. The 
diet was either placed directly into bowls and placed in the animal housing or stored in a 
refrigerator to prevent spoilage.
(2.3.5) Administration of Compounds
Pressor agents (phenvlephrine & angiotensin ID
Both pressor agents used in the experiments described were administered by the i.v. route 
and so were dissolved in physiological saline. Both pressor agents were stored in a freezer 
overnight and on ice during experiments to prevent decomposition.
Pioglitazone
Typically experiments carried out involving pioglitazone consisted o f two groups o f 
animals on test, a pioglitazone treated group and a vehicle treated group. Pioglitazone was 
dissolved in polysorbate vehicle to give a final concentration of 30 mg m kh Pioglitazone 
was dosed orally to provide 30 mg kg-1 to each animal on test in the treated group (i.e., 0.3 
ml of the 30 mg m pl drug solution was dosed to a 300g animal). Animals in the control 
group were orally dosed with an equivalent volume of polysorbate (i.e., a 300 g rat was 
dosed with 3 ml o f polysorbate). Dosing occurred once daily (at around 9:00 am) for seven 
days. After the final dose the animals were pithed and their vascular reactivity to pressor 
agents was assessed (using the protocol described in section 2 .2 . 1 ).
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(2.3.6) Statistical Methods
All statistical calculations included in this thesis were carried out using the statistic tools 
o f the Microsoft Excel 5 spreadsheet package running on an IBM PS2 PC under the 
Microsoft Windows 3.11 operating system. The tests used were the paired and unpaired 
student's t-test. The following statistical convention was used in this thesis :
* f<0.05
** f < 0 . 0 1  
*** f <0 . 0 0 1
2 8
Section Three 
Results
3.1 Initial Zucker Rat Experiments
As described in the introduction section, literature evidence suggests that IR may be linked 
to increased vascular reactivity and hypertension. The following experiments were carried 
out using small groups of insulin sensitive lean and insulin resistant obese Alderley Park 
strain Zucker rats. These experiments were carried out as "sighting" experiments both to 
make an initial assessment of the BP levels and vascular reactivities o f the two phenotypes 
but more importantly to determine the best experimental methodologies and conditions to 
adopt in studying both phenotypes o f the Zucker rat.
3.1.1 Measurement of Blood Pressure and Vascular Reactivitv in Conscious Zucker rats 
Introduction
The first experiment carried out was designed to provide an insight into the relative BP 
levels o f the lean and obese Zucker rat and also to investigate whether the two phenotypes 
had different vascular reactivities to i.v. phenylephrine administration.
Five obese AP Zucker rats were used in this study along with five of their lean 
counterparts. The rats were male and aged three and a half to four months. Briefly, rats 
were cannulated under anaesthesia and allowed to recover. Measurements o f BP and 
vascular reactivity were made 24 hours later. A full description of the methodology used in 
this experiment was given in the methods section (in section 2.3.1) but, briefly, basal BP 
and changes in BP caused by phenylephrine were measured by connecting the arterial 
cannula of each animal to a pressure trandsducer while the animals were held in restraining 
tubes. The pressor agent used in this experiment was phenylephrine at doses o f 1 ,3 , 10 and 
30 pg kg-1.
30
Results
Table 3.1 Conscious Blood Pressure values (inmHg) o f Lean and Obese Zucker Rats
Obese Rats
1 2 3 4 Mean s.e.
Systolic BP 135 135 145 130 136 3.1
Diastolic BP 95 90 105 85 94 4.3
Lean Rats
1 2 3 4 Mean s.e.
Systolic BP 150 145 145 135 144 3.1
Diastolic BP 115 115 105 105 1 1 0 2.9 P<0.05*
* by unpaired t-test
It was found that the lean Zucker rats had greater BP values than the obese animals (see 
table 3.1 above). A significant difference was found between the diastolic BP values o f the 
two phenotypes (P<0.05 by unpaired t-test) despite the small group sizes tested. However, 
despite demonstrating a lower basal BP the obese rats demonstrated slightly greater pressor 
responses to phenylephrine than their lean littermates. The differences between the vascular 
responses were statistically significant at the 10, 30 and 100 pg kg"l phenylephrine doses 
(P<0.05, P<0.05 and P<0.005 respectively by unpaired t-test), despite the small number of 
animals tested. The vascular responses o f the two phenotypes to i.v. phenylephrine are 
represented graphically in Figure 3.1.1.
Conclusions
Earlier BP measurements using radio-telemetry techniques carried out, in our work group, 
on lean and obese AP Zucker rats demonstrated that the obese rats were hypertensive 
relative to their lean counterparts (these results are summarised in Appendix 1).
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These data support the literature data which indicate that the obese Zucker is hypertensive 
compared to its lean counterpart. Due to the fact that the data was obtained from less 
stressed animals, the radio-telemetry data (considered along with the literature precedent) 
indicated that the conscious BP measurement obtained from the experiment described 
above may have given a false impression o f the BP levels of the lean and obese animals 
(especially as it was found that the obese rat had a greater vascular reactivity than its lean 
counterpart).
3.1.2 Experiment in Anaesthetised Rats 
Introduction
The experiment described in section 3.1.1 demonstrated that factors such as surgical stress 
may have important effects on the haemodynamic profile of the Zucker rats tested. In order 
to examine the vascular responses o f the two Zucker rat phenotypes without the stress 
caused by recovery surgery, animals were cannulated and their vascular responses assessed 
under anaesthesia without recovery.
Rats were anaesthetised with Intraval at 30 mg kg“l via the i.p. route. The carotid artery 
and jugular vein were cannulated (as described in the methodology for the conscious 
experiment) but there was no need for the cannulae to be exteriorised as no recovery was to 
be allowed. The BP and heart rate of the animals were monitored to assess the depth o f 
anaesthesia. The assessment of the vascular responses of the animals to pressor agents was 
carried out in the same manner as described in the pithed animal methodology (section 
2.3.2).
This study used lean and obese AP Zucker male rats of the same age as those used in the 
conscious experiment described above (section 3.1.1). The pressor agents used in this 
experiment were phenylephrine at 3, 10, 30 and 100 pg kg'l and angiotensin II at 10,30, 
100, 300 and 1000 ng kg 'h
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Results
During the course o f the experiment it was found necessary to continually provide more 
and more anaesthetic to the obese rats to maintain an adequate depth o f anaesthesia. The 
lean rats only required the initial anaesthetic dose to maintain a good depth o f anaesthesia 
throughout the entire experiment. This difference between the two phenotypes was 
probably due to the large adipose content in the obese animals and the lipophilicity o f the 
Intraval anaesthetic used. Due to this problem it may have been the case that the two 
phenotypes were at slightly different depths of anaesthesia during the experiment and 
would probably have had different concentrations o f anaesthetic in the circulation which 
may have influenced the results obtained from the dosing of the two pressor agents.
The difference between the obese rat response and the lean rat response to phenylephrine 
were not statistically significant due to the large variation in responses of the obese 
animals. The vascular responses of the lean and obese rats to phenylephrine dosing are 
represented graphically in Figure 3.1.2. The vascular responses o f the lean and obese rats 
to angiotensin II dosing were significantly different, especially at the lower concentrations 
o f the pressor agent, and are represented graphically in Figure 3.1.3.
Conclusions
Despite the problems found in maintaining a stable depth of anaesthesia, the obese 
animals had a consistently greater vascular response to both phenylephrine and angiotensin 
II dosing than was found in the lean animals (although this difference was not statistically 
significant when phenylephrine was used). This difference in vascular reactivity was 
similar to that found in the experiment on conscious animals described previously.
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3.1.3 Experiment in Pithed Rats 
Introduction
Due to the different anaesthetic handling properties of the two AP Zucker rat phenotypes 
outlined above, it was decided that it was necessary to use a preparation in which the 
influence of anaesthesia was reduced. The experiment in conscious rats, as described in 
section 3 .1 . 1  above, demonstrated that animals used in a recovery experiment may be 
affected by surgical stress. The only other type of preparation in which the animals are 
relatively free of anaesthesia is a pithed preparation. The full methodology for the pithed 
rat experiment is described in the materials and methods chapter (section 2 .1 ).
In this initial experiment groups of four male lean and four obese AP Zucker rats aged 
three and a half months were used. The pressor agents used in this experiment were 
phenylephrine at doses of 3, 10, 30 and 100 pg kg"l and angiotensin II at 10,30, 100, 300 
and 1 0 0 0  ng kg'T
Results
It was found that the obese rats demonstrated greater vascular responses to both 
phenylephrine and angiotensin II than the lean rats. The vascular responses of the lean and 
obese rats to phenylephrine are represented graphically in Figure 3.1.4. The vascular 
responses of the lean and obese rats to angiotensin II dosing are represented graphically in 
Figure 3.1.5.
Conclusions
The pithed experiment provided similar data to that from the conscious and anaesthetised 
experiments described above in that a greater vascular responsiveness was found in the 
obese Zucker rat compared to its lean counterpart. It was assumed that the results obtained
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from the pithed preparation were relatively free of the influence of surgical stress and 
different depths of anaesthesia in both of the Zucker rat phenotypes.
The experiments described in the previous sections demonstrated that two main factors 
must be taken into account when investigating the haemodynamic responses of the lean and 
obese AP Zucker rat, these being surgical stress and anaesthesia. It was concluded that the 
pithed methodology was the best to use when comparing the vascular reactivities o f the 
two AP Zucker phenotypes.
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(3.2) The Effect of a High Fat Diet on the Vascular Reactivitv of the AP Wistar Rat.
Introduction
Literature reports have indicated that a high fat diet can induce an insulin resistant state in 
experimental animals (see introduction). The high fat diet used (composed of 60 % ground 
normal diet with 30 % lard and 1 0  % caesin) has been shown to increase both plasma 
insulin and glucose in AP Wistar rats. Plasma insulin and glucose measurements from 
Wistar rats fed this diet for a period of four weeks indicated that a degree of IR was 
induced by this diet (typical results are summarised below). These results were obtained by 
other workers at Zeneca using AP strain Wistar rats.
Table 3.2.1 The Effects o f High Fat Feeding on Plasma Insulin and Plasma Glucose 
Levels in AP Wistar Rats
Plasma insulin Levels (ng mk^)
Sample (n=) mean s.e.
Control 4 0.61 0.15
Week I 1 0 1.92 0.28
Week 2 6 L 8 6 0.52
Week 3 5 L 0 2 0.79
Week 4 6 2.64 0.69
Plasma Glucose Levels (mM)
Sample (n=) mean s.e.
Control 4 7.05 0.45
Week 1 1 0 8.17 0.41
Week 2 6 &32 0.36
Week 3 5 9.22 0.17
Week 4 6 12.45 1.71
Since the high fat diet has been shown to increase plasma insulin and glucose levels it was 
decided to test the ability of the diet to alter the vascular reactivity of the AP wistar rat. 
Male AP Wistar rats of three months of age were used. One group of rats was placed on 
the high fat diet for a period of six weeks while a second group was placed on normal
41
ground diet prior to the assessment o f vascular reactivity to phenylephrine. The assessment 
o f vascular reactivity was carried out in an identical manner to that in the pithed Zucker rat 
experiments described previously.
Results
It was found that only very small differences existed between the vascular responses of 
the AP Wistar rats fed a control diet and those fed the high fat diet. A statistically 
significant difference was found between the control fed and high fat fed groups (P<0.05 
by unpaired t-test) only at the 100 pg kg 'l phenylephrine dose. These results are expressed 
graphically as Figure 3.2.1.
Conversely it was found that the group of Wistar rats fed the high fat diet demonstrated 
slightly smaller angiotensin II induced BP increases when compared to the control group 
fed a normal diet. This small difference was only statistically significant at the 100 ng kg-1 
dose (P<0.05 by unpaired t-test). These results are presented graphically as Figure 3.2.2.
Conclusions
It was found that the imposition of a high fat diet did not increase the vascular 
responsiveness of the AP wistar rat. Other experiments using the same high fat diet regime 
on AP Wistar rats implanted with radio-telemetry equipment was carried out by other 
workers at Alderley Park These experiments demonstrated that the diet did induced greater 
weight gain in the fat fed rats (compared to a control group fed a normal diet) but that no 
blood pressure increase was induced by the diet.
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(3.3) The Effects of Pioglitazone on The Vascular Reactivity of the AP Zucker Rat.
Introduction
In the initial experiments carried out on the AP Zucker rat (outlined above in section 3.1), 
the obese AP strain Zucker rat consistently demonstrated a greater vascular reactivity than 
its lean littermate. Literature reports (as described in the introduction) indicate that IR may 
be linked to haemodynamic changes. In order to further investigate the link between IR and 
vascular reactivity in the obese Zucker rat, it was decided to investigate whether an insulin 
sensitising agent could affect the haemodynamic profile of the animal.
The insulin sensitising agent chosen was pioglitazone, an orally active thiazolidenedione 
compound. The dosing regime chosen for the following experiments was based on results 
from the dosing of the compound to telemetered AP obese Zucker rats (see Appendix 1 for 
a full review of this experiment).
Experiment One
Introduction
A sighting experiment was carried out in small groups o f lean and obese male AP Zucker 
rats o f approximately six months of age. Five obese and five lean rats were treated with 30 
mg kg 'l pioglitazone once daily p.o. for seven days. In addition, five lean and five obese 
animals were dosed in an identical manner except polysorbate (vehicle) alone was used.
Results
As found in previous experiments, the obese Zucker rats treated with vehicle 
demonstrated greater vascular responses to phenylephrine than the lean rats treated with 
vehicle. A significant difference was found between these groups at the 100 pg kg"l 
phenylephrine dose (P<0.05 by unpaired t-test). The obese rats treated with pioglitazone
45
demonstrated significantly smaller responses to phenylephrine than obese rats treated with 
vehicle alone (P<0.05 at both the 3 and 10 pg kg 'l doses and P<0.01 at the 30 and 100 pg 
kg 'l doses). The vehicle treated and pioglitazone treated lean rats demonstrated no 
significant differences in their responses to phenylephrine. These results are presented 
graphically as Figure 3.3.1.
Conclusions
Despite the small group sizes used in this sighting study two observations were made. 
Firstly, the greater reactivity o f the obese Zucker compared to its lean littermate was again 
present. Secondly, statistically significant differences were found between the obese rats 
treated with pioglitazone and those treated with vehicle alone.
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Experiment Two 
Introduction
In the second experiment, due to a brief unavailability of male rats, a larger pioglitazone 
dosing study was conducted in groups o f female lean and obese AP Zucker rats. The 
female rats were slightly younger than the male rats used in the sighting experiment 
described above (being aged approximately four months). Ten obese rats were dosed with 
pioglitazone (using the same protocol as described above) as were ten lean rats. Ten obese 
and ten lean rats were dosed with polysorbate vehicle alone.
Results
As found in the previous experiment with male rats, the female obese Zucker rats treated 
with vehicle demonstrated greater vascular responses to phenylephrine doses than the lean 
rats treated with vehicle. These differences were statistically significant at the 3, 10 and 
100 pg kg"l phenylephrine doses (P<0.05, P<0.01 and P<0.05 respectively by unpaired t- 
test). The female obese rats treated with pioglitazone demonstrated significantly smaller 
responses to phenylephrine than obese rats treated with vehicle alone (P<0.05 at the 10 and 
100 pg kg"l phenylephrine doses and P<0.01 at the 30 pg kg'l dose by unpaired t-test).
The vehicle treated and pioglitazone treated lean rats demonstrated no significant 
differences in their responses to phenylephrine. These results are presented graphically as 
Figure 3.3.2.
Conclusions
The results obtained from this larger group of female rats agreed with the results from the 
smaller study using male rats in that a reactivity differential between the obese and lean 
animals was again present and pioglitazone significantly reduced the enhanced reactivity of 
the obese animal.
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Experiment Three
Introduction '
When a larger group o f male rats became available a larger pioglitazone dosing study was 
carried out to confirm the observations made from the sighting study and the female rat 
study. In this study ten obese animals were dosed with pioglitazone and a further ten with 
polysorbate vehicle alone.
Results
The male obese rats treated with pioglitazone demonstrated significantly smaller 
responses to phenylephrine than obese rats treated with vehicle alone (P<0.01 at the 3 
andlO pg kg'l doses and P<0.05 at the 100 pg kg'^ phenylephrine dose by unpaired t-test). 
These results are presented graphically as Figure 3.3.3.
Conclusions
The results from this larger study using male rats agreed with both the smaller male study 
(described in section 3.3.1.) and the study using female rats (described in section 3.3.2.) in 
that pioglitazone again produced a significant reduction in the vascular reactivity o f the 
obese AP Zucker rat. In the first two experiments the pioglitazone treated obese rats 
demonstrated a very similar level of reactivity to the vehicle and pioglitazone treated lean 
Zucker rats. One implication that may be drawn from these experiments is that pioglitazone 
is able to reduce hyper-reactivity in the insulin resistant obese Zucker rat by means o f the 
insulin sensitising properties of the agent.
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(3.4) The Effects of Pioglitazone Treatment on the Vascular Reactivity o f AP Wistar and 
AP SH Strain Rats.
Introduction '
The results obtained from the pioglitazone treatment of the obese and lean AP Zucker rat 
suggested that pioglitazone had selective effects in the obese rat. The main implication that 
may be drawn from this observation, given that pioglitazone is a known insulin sensitising 
agent, is that the fall in vascular reactivity seen in the obese AP Zucker rat is as a result of 
an increase in insulin sensitivity (i.e., due to a decrease in IR). The inference from this 
argument would be that the vascular reactivity of the lean rats was unaffected due to the 
normal insulin sensitivity of the lean phenotype.
In order to assess the selectivity o f action of the pioglitazone treatment it was decided to 
test the ability of the agent to alter the vascular responses of two alternative rat strains, the 
normotensive AP Wistar rat and the hypertensive (and hyper-reactive) AP SH rat.
Both the AP Wistar and AP SH strain rats used in this study were male and aged 
approximately four months. As in previous experiments, one group of the animals was 
dosed with pioglitazone once daily for seven days and another group was dosed in the same 
manner with polysorbate vehicle alone. At the end of the dosing period the vascular 
reactivity o f the two groups was assessed in the same manner as described previously.
Results
The vascular reactivity of the AP Wistar rat was found to be very similar to that o f the 
obese AP Zucker rat. The pioglitazone dosing produced no significant decrease in the 
vascular reactivity of the AP Wistar rat. The vascular reactivities of the control and 
pioglitazone treated Wistar rats are presented as Figure 3.4.1.
As expected, the vascular reactivity of the control treated AP SH rats was greater than that 
of the AP Wistar rats. Despite this greater reactivity, however, no difference could be
52
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seen between the control and pioglitazone treated SH rats. These results are presented 
graphically as Figure 3.4.2.
Conclusions
The experiments described in this section demonstrated that the same pioglitazone 
treatment regime that was effective in reducing the vascular reactivity of the obese AP 
Zucker rat in previous experiments was ineffective in altering the vascular responses o f the 
two rat strains tested.
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(3.5) The Effects o f Pioglitazone on the Blood Pressure o f the AP SH Rat as Measured by a 
Radio-telemetry System
Introduction
In the experiments described above and in other experiments carried out within our work 
group, pioglitazone has been shown to decrease both the vascular reactivity and the BP of 
the obese AP Zucker rat (see Appendix 1). In contrast, the agent has been shown to be 
ineffective in altering the vascular reactivity of the lean AP Zucker rat, the AP Wistar rat 
and the AP SH rat.
In an experiment carried out within our work group using a radio-telemetry system, as 
described in Appendix 1, pioglitazone was shown to decrease the BP of the obese rat and, 
to a much lesser effect, the lean AP Zucker rat. It was not clear from this experiment 
whether pioglitazone produced the greater effect in the obese animal due to a selective 
mechanism (i.e., in altering the insulin resistant state of the animal) or merely due to the 
fact that the obese animal had a higher starting BP. It was decided to test the ability of 
pioglitazone to affect the BP of the AP SH rat (which consistently demonstrates a much 
higher basal BP than the obese AP Zucker rat).
Results
Due to the normal daily activity pattern of the rats tested, the results obtained from this 
experiment have been divided into day time and night time means. Significant differences 
were found between the systolic, mean and diastolic BP values (both during the day and 
night time halves of the daily light cycle) observed after four days of polysorbate (vehicle) 
dosing and those observed after four days of piolitazone dosing (by paired t-test). Data 
from the four day time-point for both the vehicle and drug treatment periods were studied 
as they were comparable to the time-points measured in the study of pioglitazone treatment 
in obese and lean AP Zucker rats (see Appendix 1).
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Table 3.5.1 The Effect o f Oral Pioglitazone at 30 mg kg~^ d a v  ^ on the Blood Pressure. 
Heart Rate and Activity Level o f AP SH rats (n=4)
Day Time Means
Systolic BP Diastolic BP Heart Rate Activity Level 
(mmHg) (mmHg) (bpm) (units)
Control Period 208 145 310 15
Treated Period 201 138 306 14
Night Time Means
Systolic BP Diastolic BP Heart Rate Activity Level 
(mmHg) (mmHg) (bpm) (units)
Control Period 216 151 351 36
Treated Period 204 139 351 31
Please refer to Figure 3.5.1 and Figure 3.5.2 to view the daily mean results from this 
experiment presented graphically.
Conclusions
In this experiment pioglitazone dosing produced small but significant decreases in both 
day time and night time blood pressure levels in the AP SH rats tested. No significant 
effects were seen on the heart rate of the animals tested.
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(3.6) The Effects of Two Other Insulin Sensitising Agents on the Vascular Reactivity of 
the AP Zucker Rat.
Introduction
Previous experiments, described above, bave demonstrated that the insulin resistant obese 
AP Zucker rat is hypertensive and has an enhanced vascular reactivity when compared to 
its lean littermate. Furthermore, it has been demonstrated that pioglitazone, an orally active 
insulin sensitising agent, reduced both the BP and vascular reactivity of the obese rat. One 
implication that can be drawn from this observation is that pioglitazone was effective in 
reducing vascular reactivity and BP as a result o f its insulin sensitising properties (i.e., that 
the haemodynamic changes seen in the obese rat were the result o f an improvement in 
insulin sensitivity).
In order to further investigate the link between the insulin resistant state and vascular 
reactivity it was decided to dose two other insulin sensitising compounds (unrelated to 
pioglitazone) to groups o f obese and lean AP Zucker rats and assess the effect o f the 
treatment on the vascular reactivity of the animals.
With the literature reports in mind (as outlined in the introduction section), it was decided 
to use ZD2079 (a B-3 adrenoceptor agonist) and vandyl sulphate (a vanadium containing 
compound) as alternative insulin sensitising treatments in obese AP Zucker rats and to 
assess the effects of the two treatments on the vascular reactivity of the animals. 
Measurements of plasma insulin and glucose were not obtained in this experiment, 
however the drug treatment regimes applied were reproduced exactly from the literature 
reports of experiments that demonstrated clear improvements in the insulin sensitivity of 
the Zucker rats (W ilbraham  et al., 1994 and Ozcelikay et al., 1994).
Thirty female lean and thirty female obese AP strain Zucker rats, approximately four 
months old, were used in this study. The animals were caged in pairs. In each o f the lean 
and obese animal groups, five pairs were dosed with ZD2079, five pairs with vanadyl 
sulphate and five pairs were given no drug treatment and acted as a control group.
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Vanadyl sulphate (Sigma) was dosed to the animals in the drinking water. The agent was 
present in the drinking water at a concentration of Img ml"^ and the water was available to 
the animals ad lib. This dosing regime was identical to that used by Ozcelikay et al., 
(1994) whose experiment was outlined in the introduction section.
ZD2079 (Zeneca) was dosed at 50 mg kg 'l d a y l to the rats and was mixed into the 
ground rat diet provided. Fluctuations in the weights of the animals on test and their food 
intake were measured and the amount of drug placed in the diet corrected to produce the 
final dose of 50 mg kg"l per day as described above.
The body weights, food and water intakes o f the animals were measured on a regular 
basis prior to drug treatment to establish the normal basal values for each parameter. Once 
these basal measurements had been obtained, drug treatment was commenced (the body 
weights, food and water intakes of the animals were continually recorded during the drug 
dosing period).
The vanadyl sulphate dosing was commenced four weeks prior to the ZD2079 dosing. 
This was done to ensure that the three month vanadyl sulphate and the two month ZD2079 
dosing periods ended simultaneously and so the vascular reactivities of the animals could 
be assessed at the same time.
Results
No significant differences were found between the groups of obese rats prior to the 
starting of drug treatments. The starting weights of the rats were 336.7 + 9.2 g in the 
control group, 325.3 + 6.6 g in the ZD2079 group and 345.5 + 4.9 g in the vanadyl sulphate 
group (all groups contained ten rats).
The two drug treatments had significant effects on weight gain in the obese AP Zucker 
rats. At the end of the drug dosing period (i.e., at the time of pithing) the rats in the control 
group weighed 529.2 + 21.0 g, the rats in the ZD2079 group weighed 418.2 + 12.3 g and 
the rats in the vanadyl sulphate group weighed 431.9 + 11.3 g. The difference between the 
control animal weights and the ZD2079 treated animal weights was statistically significant
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( f  <0.001 by unpaired t-test) as was the difference between'the control and vanadyl 
sulphate treated rats ( f  <0.001 by unpaired t-test).
The ZD2079 treatment reduced the weight gain of the obese animals. The treated animals 
gained weight at the rate o f 0.9 ±  0.4 g day-1 while, over the same period, the control 
animals gained 1.8 + 0.3 g d a y h  The vanadyl sulphate treatment produced a similar effect, 
the treated animals gained 0.8 ±  0.4 g d ay  1 while the control animals gained 2.0 + 0.3 g 
d ay  1 over the same time period.
The ZD2079 treatment, after producing an initial fall in food intake, subsequently 
produced a slight increase in the daily food intakes o f the obese AP Zucker rats. Each of 
the treated animals consumed an average o f 27.3 ±  1.1 g d a y l of diet during the treatment 
period while the animals on control diet consumed 24.3 + 0.6 g d ay  1 during the same 
period. The water intake mirrored the food intake in the ZD2079 treated animals in that an 
initial fall in intake was followed by an overall increase. After the initial fall in water intake 
each ZD2079 treated animal consumed 32.0 ± 1.5 ml d ay  ^  while the each control treated 
animal consumed 25.3 + 1.1 ml d ay h
Vanadyl sulphate treatment produced large falls in both food and water intakes in the 
obese AP Zucker rats. During the drug dosing period the vanadyl sulphate treated animals 
each consumed 17.6 + 0.3 g d ay  1 of diet while the control group of rats each consumed 
24.5 + 0.5 g day  T The water intake of the vanadyl sulphate treated animals also was 
reduced compared to the control group, the treated animals each consumed 12.2 + 0.6 ml 
d ay  1 while the control animals each consumed 25.5 + 1.0 ml d ay  h
No significant differences were detected between the groups of lean rats prior to the start 
o f the two drug treatments. The starting weights of the rats were 183.6 + 3.6 g in the 
control group, 171.0 ±  7.3 g in the ZD2079 group and 179.9 ±  4.3 g in the vanadyl sulphate 
group (all groups contained ten rats).
At the end of the dosing periods (i.e., at the time of pithing) the lean rats of the control 
group weighed 232.9 + 4.8 g, the ZD2079 treated rats weighed 217.7 + 9.2 g and the 
vanadyl sulphate treated animals weighed 206.4 ±4.1 g.
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The two drug treatments had less effect on weight gain in lean than in obese animals. The 
rats treated with ZD2079 gained weight at the same rate as the control animals (0.5 ±  0.1 g 
day-1). The vanadyl sulphate treated rats gained an average of 0.3 + 0.2 g day-1 while the 
control animals gained 0.5 + O.l 'g day-1 over the same period.
The two drug treatments were much less effective in altering food and water intakes in 
the lean rats compared to their effects in the obese animals. The vanadyl sulphate treated 
animals each consumed 14.6 + 0.3 g day-1 of diet compared to the intake o f 16.7 ±  0.1 g 
day-1 in the control group over the same time period. The water intakes o f the vanadyl 
sulphate treated animals was 13.7 + 0.6 ml day-1 compared with 21.1 + 0.5 ml day-1 in the 
control group.
The ZD2079 treatment again produced an initial transient decrease in food and water 
intakes in the lean Zucker rats followed by a sustained increase. Treated animals each 
consumed 18.1 + 0.2 g day-1 of diet compared to an intake of 16.7 + 0.1 g day-1 over the 
same period in the control animals. Treated animals each drank 22.1 + 0.7 ml day-1 of 
water compared with an intake of 21.2 + 0.5 ml day-1 in the control group.
Significant differences were found between the blood pressure responses to phenylephrine 
doses in the control lean and obese rats. These results are outlined in Table 3.6.1 below.
Table 3.6.1 : Lean and Obese AP Zucker rat Blood Pressure Responses to i.v. 
Phenvlenhrine
Phenvlenhrine Increase in dBP fnunHg) Significance*
(pg kg-1) Obese Rats Lean Rats
(n=10) (n=9)
1 10+2.9 7±1.3 NS
3 21+5.6 16+4.4 NS
10 72+12.9 56+8.4 NS
30 117±7.4 95±5.9 P<0.05
100 143+7.0 125+5.4 P<0.01
* by unpaired t-test
This data collection is also represented in graph format as Figure 3.6.1.
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These results are very similar to those seen previously when both male and female lean 
and obese AP Zucker rat reactivities were compared in similar aged animals. Previous 
results have also demonstrated that pioglitazone was capable of reducing the increased 
reactivity observed in the obese animals. '
(2) Drug Effects on Vascular Reactivitv in the Obese Rats
The two drug treatments failed to produce any significant effects on the vascular 
reactivity o f the treated obese rats.
Table 3.6.2 : The Effects o f the Two Drug Treatments on the Vascular Reactivitv o f the 
Obese AP Zucker Rats.
Phenvlenhrine Increase in dBP TmmHg)
(p g k g 'l)  Control Rats ZD2079 Treated Vanadvl Sulphate Treated
(n=10) (n=9) (n=10)
1 . 10+2.9 7+2.4 10+2.8
3 21+5.6 20±7.5 22±7.7
10 72+12.9 75+9.7 72+15.8
30 117±7.4 112+2.2 110+16.1
100 143±7.0 136±3.6 143+9.7
These results are expressed graphically as Figure 3.6.2.
(3) Drug Effects on the Vascular Reactivitv of the Lean Rats.
Both drug treatments failed to produce any alterations in the vascular responses o f the 
lean Zucker rats in this experiment.
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Table 3.6.3 : The Effects o f Drug Treatment on the Vascular Reactivity of the Lean AP 
Zucker Rats.
Phenylephrine Increase in dBP (mmHsl
(|igkg"l) Control Rats ZD2Q79 Treated Vanadyl Sulphate Treated
(n=9) (n=9) (n=8)
1 7±1.3 11+2.6 8±3.1
3 16+4.4 21±4.6 12+2.7
10 56±8.4 65±6.7 54+6.1
30 95+5.9 93±4.5 96±10.1
100 125±5.4 117±4.8 131±8.5
These results are expressed graphically as Figure 3.6.3.
Comments
In this experiment the yascular reactiyity difference between the lean and obese AP 
Zucker rats was again obseryed (which implied that the yasculature of the obese animals 
tested was hyper-reactiye). The two drug treatments produced no alteration of the yascular 
reactiyity o f either the lean or the obese animals tested despite significant alterations in the 
body weight and food and water intakes o f the obese rats in particular.
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Section Four
Discussion
In this section the results are discussed in the context of the original aims o f the project 
(as set out in the introduction section). The aims of the project were to :
(1) Determine if a functional difference existed between the vasculatures o f animals with 
normal insulin sensitivity and those of animals with impaired insulin sensitivity.
(2) Determine how insulin sensitising agents affect the vascular reactivities o f insulin 
resistant and insulin sensitive animals.
(3) Determine if  any effects observed on the vascular reactivity o f insulin resistant 
animals influence the blood pressure of the animals.
f i l l s  Insulin Resistance Associated with an Increased Vascular Reactivitv ?
As stated at the outset of the project, it was hoped to investigate both an experimentally 
induced (dietary) and a spontaneous (genetic) animal model o f IR and to examine the 
vasculatures o f each model with reference to a comparable animal with a normal insulin 
sensitivity.
In the experiment described in section 3.2, the high fat diet failed to induce an increase in 
the vascular reactivity o f the AP Wistar rat. It must be stated that no measurements of 
insulin and glucose were made during this experiment so the insulin resistant state o f the 
rats could not be demonstrated. However, as described in the results section, the 30 % fat 
diet used in this study had been shown to induce decreased insulin sensitivity over a similar 
treatment period in the AP Wistar rat in experiments carried out at Alderley Park.
Evidence from the literature on experiments where dietary manipulation has been used to 
bring about IR (and hence vascular reactivity and BP changes) indicates that rat strain, and 
indeed sub-strain, is an important variable. Zein et a l ,  (1990) described a study in which a 
high sucrose diet was fed to three different sub-strains of Wistar rat in an attempt to induce 
alterations in BP. It was found that the BP of Wistar-Kyoto strain rats was less responsive 
to dietary manipulation than other normotensive Wistar strains. Preuss and Preuss (1980) 
had previously published similar data, again using a high sucrose diet, demonstrating that
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the American Wistar rat was less liable to dietary-induced hypertension than the Wistar- 
Kyoto strain rat.
Another potentially important experimental variable, which was not examined in the 
study carried out as part of this project, was the composition o f the diet to which the 30% 
fat was added. It has been demonstrated that an increase in oat bran content o f rat diet can 
reduce the increased BP induced by increased sucrose ingestion (Zein et al., 1990). Zein et 
al., suggested that oat bran may have acted to prevent an increase in BP in this experiment 
by either increasing faecal water loss (lowering circulating blood volume) or by altering the 
rate of nutrient and water absorption from the intestinal lumen by decreasing the transit 
time o f material through the intestine. It may have been the case that the normal ground 
diet used in the study carried out as part of this thesis had a sufficient roughage content to 
counter the effects of the added fat by the mechanisms outlined above.
The experiment described above indicated that fat feeding had little effect on the vascular 
reactivity o f the AP Wistar rat. Further investigation of the vascular effects of fat feeding 
would involve the assessment of rat strain differences and of other components of the 
animal diet used. These experiments were beyond the scope of this study.
There is a large body of evidence in the literature that indicates that the obese Zucker rat 
is associated with marked IR (e.g., K urtz et al., 1989). A statistically significant difference 
between the vascular reactivities of the lean and obese AP Zucker rat was seen in all the 
experiments carried out as part of this project. The difference in reactivity between the lean 
and obese animals was present in both male and female Zucker rats. This difference was 
observed even in the presence of surgical stress and anaesthesia, which were a feature of 
some experiments carried out to establish a standard experimental methodology. This data 
supports the observations of Zemel et al., (1992), among others, who describe the obese 
Zucker rat as hyper-reactive compared to the lean Zucker rat. Given that the obese Zucker 
rat is insulin resistant, when compared with the lean Zucker rat, the observation that the 
obese animal has an increased level of vascular reactivity compared to the lean animal 
suggests, at the very least, that there may be an association between IR and changes in 
vascular reactivity.
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It was interesting to compare the basal reactivity levels of the two AP Zucker rat 
phenotypes with the other rats strains investigated (please refer to Figure 4.1). Various 
literature reports have described the obese Zucker rat as a model of vascular hyper­
reactivity. Given the comparisons of the vascular reactivity of the obese Zucker rat with 
that o f the AP Wistar rat and AP SH rat, it was difficult to describe the obese Zucker rat as 
an example o f vascular hyper-reactivity in the experiments carried out for this project. 
Indeed, from the results presented in figure 4.1, it may be as valid to describe the lean AP 
Zucker rat as an example o f vascular hypo-reactivity.
Despite the modest level of vascular reactivity observed in the obese animals compared 
to the Other rat strains tested, it was still true to say that the obese rats were hyper-reactive 
when compared to their lean phenotype. As the obese animals were also insulin resistant in 
comparison to their lean counterparts, it was concluded that the lean and obese Zucker rat 
phenotypes offered a valid model in which to study the link between vascular reactivity 
and IR.
(2 and 3j Do agents that improve insulin sensitivity affect vascular reactivitv and blood 
pressure ?
Given that a difference was found between the vasculatures of the obese and lean AP 
Zucker rat, more direct evidence was sought which would link the vascular difference with 
the difference in insulin sensitivity. Assuming that a known insulin sensitising agent would 
be effective in increasing the insulin sensitivity of the obese AP Zucker rat, a decrease in 
vascular reactivity due to the drug treatment would indicate that insulin sensitivity was 
linked to the vascular reactivity of the animal.
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Pioglitazone has been shown to improve insulin sensitivity in a number of animal models 
(e.g., Kemnitz et al., 1994 and Ikeda et al., 1990) including the obese Zucker rat 
(Doebber et al., 1993). In the experiments described in section 3.3, treatment with 
pioglitazone produced statistically significant falls in the reactivity of obese, but not of the 
lean Zucker rats. However, pioglitazone treatment produced this effect in both male and 
female rats. Pioglitazone produced no significant alterations in the vascular reactivity of 
either the AP Wistar rat or the AP SH rat. The AP Wistar rat has a normal insulin 
sensitivity while the insulin resistant status of the AP SH rat is controversial (as described 
in the introduction section). One implication that could be drawn from this data is that the 
pioglitazone treatment produced a decrease in the vascular reactivity of the insulin resistant 
obese Zucker rat due to the insulin sensitising properties of the agent.
It is possible that the lack of effect o f pioglitazone treatment on vascular reactivity in the 
AP SH rat could have been due to the very high reactivity of the animal. It may have been 
the case that the reactivity of the SH rat was maximal and was not sensitive to alteration by 
an agent, such as pioglitazone, with moderate vasoactive properties as the reactivity was 
still maintained via other mechanisms. Conversely, the reactivity level of the lean AP 
Zucker rat may have been too low to be reduced further by drug treatment. That said, the 
AP Wistar rat demonstrated a similar basal vascular reactivity level to the obese AP Zucker 
rat. Even assuming that the vasculatures o f the SH and lean Zucker rats were insensitive to 
drug alteration, if pioglitazone was acting via a mechanism other than one concerned with 
insulin sensitivity, it would have been expected that the agent would have produced a 
similar decrease in the vascular reactivity of the AP Wistar rat to that observed in the obese 
Zucker rat.
In the experiments described above, the insulin sensitising agent pioglitazone produced 
decreases in the vascular reactivity of the insulin resistant obese Zucker rat. This is further 
positive evidence to support the hypothesis that an insulin resistant state supports an 
increased vascular reactivity.
Work carried out using a radio-telemetry system within our group demonstrated that the 
obese AP Zucker rat was hypertensive when compared to the lean AP Zucker rat. Since
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others were also involved with this work, the results of this work are presented in 
Appendix 1. Given that an insulin sensitising agent, pioglitazone, had been shown to 
decrease the vascular reactivity o f the insulin-resistant obese rat, the effects o f the agent on 
the blood pressure levels o f the two AP Zucker rat phenotypes were o f much interest. A 
pioglitazone induced BP fall in the obese AP Zucker rat but not in the lean rat would have 
indicated that the reactivity level of the obese animal was important in maintaining the 
elevated BP level (compared to the lean animal). The results o f this experiment, which was 
carried out within our group, are presented in Appendix 1.
Pioglitazone produced small but significant decreases in the BP of both the lean and 
obese AP Zucker rat and also in the BP o f the AP SH rat. Unlike the experiments 
measuring vascular reactivity, the data from the experiments measuring the effects of 
pioglitazone on BP suggest that the agent did not just have an effect in the insulin resistant 
obese AP Zucker rat. This result is in agreement with a report in the literature in which 
pioglitazone has been shown to be a hypotensive agent in both insulin resistant animals as 
well as in animal models in which a normal insulin sensitivity is present. Zhang et al., 
(1994) demonstrated that pioglitazone treatment produced BP falls in both the insulin 
resistant Dahl salt-sensitive rat and in the one-kidney, one clip rat model (a model o f renal 
hypertension with a normal insulin sensitivity).
A comparison of the pioglitazone induced BP falls produced in the three rat strains 
indicated that, on the fourth day o f pioglitazone treatment, the basal BP of the telemetered 
rats fell, when compared to the fourth day of vehicle dosing, by an average o f 7 mmHg in 
the AP SH rat (n=4), 7 mmHg in the lean AP Zucker rat (n=8) but a larger 19 mmHg in the 
obese AP Zucker rat (n=6). When expressing these BP falls as a percentage o f the initial 
starting control BP level for each rat strain, it can be clearly seen that pioglitazone had a 
larger effect on BP in the obese AP Zucker rat (a fall of 15.4 %) than in the lean AP Zucker 
rat or the AP SH rat (falls of 6.9 % and 4.2 % respectively).
One implication that may be drawn from this data is that the larger BP fall seen in the 
pioglitazone treated obese AP Zucker rat was connected with the reduction in vascular 
reactivity induced by the same pioglitazone treatment, as demonstrated in the experiments 
on pithed animals described previously. Thus, these experiments may also demonstrate,
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although indirectly, that the enhanced reactivity o f the obese Zucker rat may help to 
support a hypertensive state.
A major criticism o f the experiment using vanadyl sulphate and ZD2079 as insulin 
sensitising agents (and indeed of the other experiments carried out as part o f this project) is 
that no measurements o f insulin and glucose were made. Because o f this, no measure of 
insulin sensitivity, and hence changes in insulin sensitivity, o f the treated rats was 
obtained. That said, both the vanadyl sulphate and ZD2079 treatment regimes used in this 
experiment produced definite changes in the metabolism of the obese and lean AP Zucker 
rats, as evidenced by the changes in weight gain and food and water intake o f the animals, 
in comparison with the control treated group o f animals. In view of these changes, and the 
literature precedent with the two treatment regimes, it was assumed that a concurrent 
improvement in insulin-sensitivity had occurred in the animals. Despite these changes, 
however, the vascular reactivity level of both the obese and lean vanadyl sulphate and 
ZD2079 treated AP Zucker animals remained unaltered from that of the untreated, control, 
animals. Therefore, improvements in insulin sensitivity may not always result in a 
decreased vascular reactivity in insulin resistant animals.
The vanadyl sulphate treatment regime used in this experiment has been shown to 
decrease the reactivity of blood vessels from treated animals when reactivity was 
measured in vitro (Ozcelikay et al., 1994), so it was surprising that no decrease in vascular 
reactivity was observed in this experiment. Other literature reports, however, have 
demonstrated that vanadium containing compounds have the ability to enhance protein 
tyrosine phosphorylation (via an inhibition o f tyrosine phosphatase) and cause a direct 
constriction o f blood vessels (Laniyonu et al., 1994 and Di Salvo et al., 1993). One 
explanation for the apparent lack o f activity o f vanadyl sulphate treatment on vascular 
reactivity in this experiment may be that vanadyl sulphate induced two counteracting 
effects on the vasculature of the treated animals, a decrease in reactivity due to an 
improved insulin sensitivity and a simultaneous increase in reactivity due to an inhibition 
of tyrosine phosphatase.
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Insulin itself has also been demonstrated to potentiate contractile responses in vascular 
tissue. H enrion and L aher (1994) demonstrated that insulin potentiated the contractions 
o f rabbit facial arteries induced by noradrenaline. These authors demonstrated that insulin 
produced this potentiation via increases in activation of protein kinase C and tyrosine 
kinases. This observation leads to the possibility that, in the experiment using vanadyl 
sulphate and ZD2079 as insulin sensitising agents in the obese AP Zucker rat, increases in 
insulin sensitivity potentiated both a relaxant and a contractile effect o f insulin causing no 
net change in the overall vascular reactivity of the obese AP Zucker rat.
The dual effect o f vanadate on the vasculature, i.e., vanadium containing compounds 
being capable o f causing both an increase and a decrease in vascular reactivity, is also 
reflected in the literature of studies investigating the effects of the vanadium containing 
compounds on BP. Bhanot and McNeill (1994) described a set o f studies in which 
vanadyl sulphate treatment caused reductions in both plasma insulin and BP levels in SH 
rats but not in normotensive Wistar-Kyoto rats. Bhanot et al., (1994) describe further 
studies in which treatment with vanadyl sulphate prevented the BP rise caused by fructose 
feeding in male Sprague-Dawley rats. Conversely, Bursztyn and M ekler (1993) reported 
that treatment with vanadate induced hypertension in male Sabra rats by increasing their 
salt-sensitivity. Interestingly, the authors also found that the vanadate treated rats had an 
increased vascular responsiveness to i.v. angiotensin II administration compared to rats that 
had not been treated with vanadate.
Many studies have demonstrated that tissues from insulin resistant animals, when 
examined in vitro, are hyper-reactive to constrictor agents when compared to tissues from 
animals with a normal insulin sensitivity (e.g., Cox and Kikta, 1992 and Zemel et al., 
1991). Possibly the most interesting feature of these studies is that they have mostly been 
carried out in the absence of any added insulin in the organ bath. Even allowing for the 
possibility that a residual amount of insulin may still have been present in the tissues 
studied, it is clear from these experiments that bathing concentrations o f insulin are not 
vital in demonstrating differences between the vascular tissues of animals with differing 
insulin sensitivities. The main conclusion from these experiments is that the tissues from
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insulin resistant animals and those from animals with a normal insulin sensitivity have 
different responses to constrictor agents regardless of local insulin concentrations (i.e., 
their in vitro responses are not different due to different sensitivity to an acute insulin 
mediated dilation effect, as no insulin is present).
A further conclusion that may be drawn from these experiments is that a chronic insulin 
resistant state produces an irreversible, or at least a long lasting, adaptive change to the 
peripheral vasculature causing it to be hyper-reactive to constrictor agents regardless of 
local insulin concentrations (perhaps similar to the effect of calcium-loading of vascular 
smooth muscle as seen in models of chronic hypertension). Such adaptive changes to 
insulin might explain the lack of effect of the vanadyl sulphate and ZD2079 treatments on 
the vascular responses of the obese AP Zucker rats. The obese AP Zucker animals used in 
the study were in a well established insulin resistant state prior to the treatment with the 
two insulin sensitising agents. Treatment with the two agents produced metabolic changes 
in the obese rats leading to an improved insulin sensitivity (as evidenced by their smaller 
weight gains compared to untreated control animals). If, however, the previously existing 
insulin resistant state had produced an irreversible adaptive change in the vasculature o f the 
animals then an improved insulin sensitivity would not have fully restored the level of 
responsiveness of the vasculature to that present prior to the onset of the insulin resistant 
state.
However, if  a permanent change is induced in the vasculature o f animals due to chronic 
IR the lack of effect o f the vanadyl sulphate and ZD2079 treatment in the obese AP Zucker 
rat in the experiments carried out for this project can be explained. It is difficult to explain 
the fact that pioglitazone was able to produce decreases in the reactivity of the obese AP 
Zucker rat vasculature. Previously it was assumed that the insulin sensitising properties of 
pioglitazone were behind the decrease in vascular reactivity of the obese AP Zucker rat i.e., 
that pioglitazone decreased the vascular reactivity of the insulin resistant rat by potentiating 
the relaxant properties o f insulin on the vasculature. The failure of both vanadyl sulphate 
and ZD2079 treatment to alter the vascular reactivity of the obese AP Zucker rat would
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suggest that such a reduction in IR does not invariably lead to a decrease in vascular 
reactivity.
This would imply that pioglitazone has actions, unrelated to its insulin sensitising 
properties, which act to decrease vascular reactivity and hence BP. Pioglitazone has been 
shown to have effects on L-type calcium channels in aortic smooth muscle cells (Zhang et 
al., 1994) and to inhibit calcium uptake by vascular smooth muscle induced by 
norepinephrine, vasopressin and potassium chloride (Buchanan et al., 1995). These 
actions would result in inhibition of vascular smooth muscle contractility and hence would 
decrease vascular reactivity even in animal models with a normal insulin sensitivity.
The experiments carried out as part o f this project have demonstrated that pioglitazone 
has a modest, but significant, hypotensive effect in the AP SH rat and the lean AP Zucker 
rat, two rat strains with, respectively, a normal insulin sensitivity and, in the case o f the AP 
SH rat, at best a modest impairment of insulin sensitivity. These data would support the 
view that the observed activity of pioglitazone was unrelated to the insulin resistant state of 
the test animal. Despite this, however, in the experiments carried out in pithed animals, 
pioglitazone only altered the vascular reactivity of obese AP Zucker rats. The conclusion 
drawn from these experiments is either that pioglitazone was acting on vascular reactivity 
by altering the insulin resistant state of the obese animal or that the obese rat possessed a 
secondary, independent, defect in its vasculature which was both sensitive to pioglitazone 
treatment and not shared by the lean AP Zucker, the AP Wistar or the AP SH rat.
Future Work
The experiments carried out as part of this project, as noted in the discussion above, 
indicated that IR has a strong link with an increased vascular reactivity but that this link 
may not be clear cut. Two main problems were found in the interpretation of the data from 
the experiments. The first of these problems was that no measurements of insulin 
sensitivity were obtained from any of the experiments. Known insulin sensitising agents 
were used during these experiments but their alterations in the reactivity of insulin resistant 
vasculatures could not be directly linked to the degree of change in insulin sensitivity. It
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would be desirable to measure the change in insulin sensitivity induced by the pioglitazone 
treatment used in the experiments described above and link them with the vascular changes 
observed.
The second problem encountered during these experiments was that the insulin 
sensitising agents used had other actions, on vascular smooth muscle in particular, which 
made drug induced vascular alterations difficult to relate purely to changes in insulin 
sensitivity. Future experiments should concentrate on attempting to demonstrate the effect 
o f a pure insulin sensitising treatment on the reactivity of the insulin resistant vasculature. 
One possible non-chemical treatment would be dieting. Ikeda et al., (1996) demonstrated 
that weight loss in obese hypertensive patients produced concurrent falls in IR, as 
measured by euglycaemic clamp studies, and systemic BP. This clinical observation 
supported earlier work such as that reported by Rocchini et al., in 1987. These authors 
demonstrated that BP falls induced by weight loss and exercise regimes in obese 
adolescents were associated with falls in plasma insulin (indicating that an improvement in 
insulin-sensitivity had been induced).
An experiment in the obese and lean Zucker rat could be carried out in which a dietary or 
exercise regime were used as an insulin sensitising treatment. Measurements of insulin 
sensitivity would be taken both prior to the imposition o f the treatment and after the 
treatment so a quantitative measure o f the improvement in insulin sensitivity could be 
obtained. The animals could be implanted with a radio-telemetry BP recording unit during 
the course of the experiment so that any alterations in BP could be recorded. At the end of 
the treatment period the animals could be pithed and the reactivity o f their vasculature 
assessed and compared to a suitable control group. This experiment would be free o f the 
problems o f drug side-effects found during this project and also provide a quantitative 
measure of alterations in insulin sensitivity which could be related to the degree of vascular 
changes found.
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Summary
I will now return to the questions posed at the start o f the project (and restated at the 
beginning of this section) and briefly put forward the key observations that go towards 
answering them.
(1) The physiology /  pathology o f  the insulin resistant vasculature.
Does a functional difference exist between the vasculatures of animals with normal 
insulin sensitivity and those of animals with impaired insulin sensitivity?
(2) The effects o f  insulin sensitising agents.
If  a difference can be observed, how do insulin sensitising agents affect the vasculatures 
o f insulin resistant and insulin sensitive animals?
In terms of vascular reactivity, the data discussed above can be divided into two 
categories, that which supports the hypothesis that IR is related to peripheral vascular 
changes and that evidence which opposes the hypothesis. Two main pieces of evidence 
indicate that IR is linked to an increase in vascular reactivity. These pieces of evidence are:
(a) the insulin resistant obese AP Zucker rat demonstrates an increased vascular reactivity 
over that of the insulin sensitive lean AP Zucker rat
(b) the insulin sensitising agent pioglitazone reduces the vascular reactivity of the obese 
AP Zucker rat but not that of more insulin sensitive animals (the lean AP Zucker, the AP 
Wistar and the AP SH rat).
The main piece o f evidence supporting the contrary stance, that IR is not necessarily 
directly linked to an increase in vascular reactivity, was produced from the experiment 
where two insulin sensitising agents, vanadyl sulphate and ZD2079, failed to alter the level 
of vascular reactivity of the obese AP Zucker rat.
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(3) The influence o f  vascular reactivity on blood pressure.
How do any effects observed on the vascular reactivity of insulin resistant animals 
influence the BP levels of the animals?
The BP levels of the obese and lean AP Zucker rats, as measured by radio-telemetry, 
mirrored the relative vascular reactivities o f the two phenotypes as measured using the 
pithed animal methodology in that the hyper-reactive obese rat was hypertensive when 
compared to the less reactive lean rat. Some slightly more direct evidence was produced 
from this project which indicated that a reduction in the vascular reactivity of the obese AP 
Zucker rat, produced by pioglitazone treatment, was associated with an exaggerated BP fall 
when compared to the BP falls induced in other rat strains whose vascular reactivity was 
unaffected by pioglitazone treatment.
8 2
Appendix One
The Blood Pressure Difference Between Lean and Obese AP Zucker Rats.
Groups of male lean and obese AP Zucker rats were implanted with radio-telemetry BP 
recording equipment as part of an experiment carried out within our work group. For a full 
explanation of the radio-telemetry system please refer to section 2.3.3. The rats tested were 
observing a normal light dependent activity pattern. The animals were housed in a room 
that provided a 12 hour light period (6:00 AM to 6:00 PM) during which the animals were 
dormant and a 12 hour dark period (6:00 PM to 6:00 AM) during which the animals were 
active. The BP levels o f the animals were directly related to their activity levels and so 
their BP levels also followed the twelve hour light and dark cycle. It was found that a 
significant BP difference existed between the lean and obese rats during both the light and 
dark periods o f the light cycle (P<0.001 by unpaired t-test in both periods). These results 
are presented in Figure A.I.
The Effect of Pioglitazone Dosing on the Blood Pressure of Lean and Obese Zucker Rats.
As part of a larger experiment carried out in our work group, pioglitazone was dosed to 
small groups o f male lean and obese AP Zucker rats which had previously had BP 
recording radio-telemetry equipment implanted. At the time of the experiment the rats 
were six months old. In the experiment polysorbate vehicle was dosed p.o. once daily to 
the test animals for a period of four days. Following this control period, pioglitazone was 
dosed at a dose of 30 mg kg'^ again once daily p.o.
The BP effects of this dosing are presented as Figure A.2 (daytime means) and figure 
A.3 (night time means).
The main conclusion drawn from this experiment was that pioglitazone produced a fall in 
both daytime and night-time BP readings in both the lean and obese AP Zucker rat. It was 
also obvious that pioglitazone produced a larger hypotensive effect in the obese animal 
(i.e., produced a differential effect in the two Zucker phenotypes).
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The pioglitazone dosing regime used in this experiment produced a haemodynamic change 
in the Zucker rat (the degree o f which appeared to be different in the lean and obese 
animals) without demonstrating any adverse side effects. It was decided to use a similar 
regime in all the experiments involving the agent carried out subsequently.
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